Advice
Following a full submission
Clopidogrel (Plavix) is accepted for restricted use within NHS Scotland for the treatment of acute coronary syndrome (without ST-segment elevation) in combination with aspirin. It should be initiated only during an inpatient stay and only in patients in whom a diagnosis of acute coronary syndrome is confirmed with ECG changes or raised cardiac enzymes/markers. The maximum benefit appears within 3 months of starting treatment and the available information suggests that there is loss of benefit on stopping treatment.
Benefits are greatest in patients with a high Thrombosis In Myocardial Infarction (TIMI) risk score (5 – 7).
Download detailed advice21KB (PDF)
Medicine details
- Medicine name:
- Clopidogrel (Plavix®)
- SMC ID:
- 88/04
- Indication:
- Prevention of atherothrombotic events in acute coronary syndrome
- Pharmaceutical company
- Sanofi-Aventis
- BNF chapter
- Cardiovascular system
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 08 March 2004